Anmol Kaur

Anmol Kaur

Auto-generated profile, based on publicly available information

Anmol Kaur

Lady Hardinge Medical College

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2025 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
MBMainak Bardhan
Mainak Bardhan
MMMuneeb Ahmad Muneer
Muneeb Ahmad Muneer
AKAbhinav Khare
Abhinav Khare
RSRushita Minesh Shah
Rushita Minesh Shah
AKAnmol Kaur
Anmol Kaur
ZCZhijian Chen
Zhijian Chen
Glioblastoma (GBM), a highly malignant brain tumor, has a poor prognosis despite standard treatments like surgery, chemotherapy, and radiation. Glioblastoma stem cells (GSCs) play a critical role in recurrence and therapy resistance. Stem cell-based therapies have emerged as innovative approaches, leveraging the tumor-targeting abilities of stem cells to deliver treatments directly to GBM. This review focuses on using intact stem cells or subtypes for GBM therapy, excluding antigenic characteristics. The stem cell-based therapies explored include neural, mesenchymal, glioblastoma, hematopoietic and adipose-derived stem cells that have been investigated in both clinical and preclinical settings. A systematic search in PubMed, EMBASE, ClinicalTrials.gov, and Scopus had identified research up until January 2024. Key mechanisms reviewed include immune modulation, angiogenesis inhibition, and apoptosis induction. Discussion of completed and ongoing trials include emphasis on safety, efficacy, challenges, and study design limitations. Stem cell-based therapies hold promise for treating GBM by targeting GSCs and improving treatment outcomes. Despite some potential advantages, challenges such as tumorigenesis risks, delivery complexities, and sustained therapeutic effects persist. Future research should prioritize optimizing stem cell modifications, combining them with current treatments, and conducting large-scale trials to ensure safety and efficacy. Integrating stem cell therapies into GBM treatment could provide more effective and less invasive options for patients.

1 November 2026 in NeuroMarkers
Verified
Journal Article
Open access
MMMuneeb ahmad Muneer
Muneeb ahmad Muneer
MHMohammad Hassan
Mohammad Hassan
HAHarshita Agarwal
Harshita Agarwal
PSPoorvikha S.
Poorvikha S.
MAMohammad Orooj Azmi
Mohammad Orooj Azmi
VSVinay Suresh
Vinay Suresh

21 November 2026 in Journal of Alzheimer’s Disease
Verified
Journal Article
Open access
ASArkansh Sharma
Arkansh Sharma
RRRishu Raj
Rishu Raj
MAMohammad Orooj Azmi
Mohammad Orooj Azmi
NPNishmitha Puchakayala
Nishmitha Puchakayala
AKAnmol Kaur
Anmol Kaur
OUOlivier Uwishema
Olivier Uwishema
Background: Sleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear. Objective: To compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs). Methods: Following PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges’ g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis. Results: Twelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD −1.09) and WASO (SMD −0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD −0.98), with favorable short-term tolerability. Walking (SMD −0.48), bright light therapy (SMD −0.37), and NITE-AD (SMD −0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD −0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects. Conclusions: Non-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.